Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Mezigdomide reverses T-cell exhaustion by degrading IKZF1/IKZF3, restoring cytokine production and enhancing target cell killing in multiple myeloma.

• Why it matters: T-cell exhaustion limits the effectiveness of T-cell engager therapies in multiple myeloma, creating a need for strategies that restore T-cell functionality and improve treatment outcomes.
• What they did: The study used transcriptomic and epigenetic profiling of exhausted T cells, revealing that IKZF1 and IKZF3 regulate exhaustion and cytokine genes, and that mezigdomide promotes their degradation.
• The result: Mezigdomide treatment decreased exhaustion markers, increased proinflammatory cytokines, and improved T-cell mediated killing, supporting its combination with TCEs to enhance multiple myeloma therapy.